Relmada Therapeutics
RLMD
75 hedge funds and large institutions have $469M invested in Relmada Therapeutics in 2020 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 20 increasing their positions, 7 reducing their positions, and 8 closing their positions.
2,074% more call options, than puts
Call options by funds: $11.2M | Put options by funds: $513K
400% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 8
186% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 7
74% more funds holding
Funds holding: 43 → 75 (+32)
47% more capital invested
Capital invested by funds: $319M → $469M (+$150M)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
6.49% more ownership
Funds ownership: 62.63% → 69.12% (+6.5%)
Top Buyers
| 1 |
BlackRock
New York
|
+$31.2M |
| 2 |
RI
RTW Investments
New York
|
+$21M |
| 3 |
State Street
Boston,
Massachusetts
|
+$11.7M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$11.6M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
+$8.46M |
Top Sellers
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$33.8M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$22.3M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$10.9M |
| 4 |
VA
VR Adviser
New York
|
-$7.37M |
| 5 |
Goldman Sachs
New York
|
-$3.62M |
RLMD Hedge Fund Activity: Q2 2020 in Review
75 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q2 2020, worth a combined $469M — up 47% from $319M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new RLMD positions and 8 closed out — a net gain of 32 holders — while 20 added to existing stakes and 7 trimmed.
The largest buyer was BlackRock, adding an estimated $31.2M. The largest seller was Tang Capital Management, cutting an estimated $33.8M.
- 75 institutional investors held Relmada Therapeutics (RLMD) as of Q2 2020, up from 43 in Q1 2020.
- Funds reported $469M of Relmada Therapeutics stock for Q2 2020, up 47% quarter-over-quarter.
- 40 funds opened new Relmada Therapeutics positions in Q2 2020 and 8 closed out, a net change of +32 holders.
- The largest Relmada Therapeutics buyer in Q2 2020 was BlackRock, an estimated $31.2M added.
- The largest Relmada Therapeutics seller in Q2 2020 was Tang Capital Management, an estimated $33.8M sold.
Based on aggregated 13F filings for Q2 2020.